Insulin detemir reduces the risk of hypoglycaemia at all levels of HbA1c compared to NPH insulin in the context of basal-bolus therapy for type 1 diabetes

被引：0

作者：

Jones, DR

Kim, H

Heller, S

Clauson, P

机构：

[1] Royal Surrey Cty Hosp, Dept Endocrinol & Diabet, Guildford, Surrey, England

[2] Univ Sheffield, Sheffield, S Yorkshire, England

[3] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark

来源：

DIABETOLOGIA | 2005年 / 48卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

243

引用

页码：A92 / A93

页数：2

共 50 条

[21] Switching from basal-bolus therapy with NPH insulin to basal-bolus therapy with the analog insulin detemir improves glycemic control and reduces hypoglycemic episodes, without weight gain, in type 1 and type 2 diabetes patients: Results from German subgroup of the PREDICTIVE study
Ruhnau, Klaus-Juergen
Hansen, Jes B.
Dornhorst, Anne
DIABETES, 2006, 55 : A133 - A133
[22] Insulin detemir is associated with lower risk of hypoglycemia compared to NPH insulin in people with Type 1 diabetes
Kolendorf, K
Prasek, M
Santeusanio, F
Philotheou, A
Gall, MA
Heller, S
DIABETOLOGIA, 2004, 47 : A329 - A329
[23] Insulin detemir is associated with lower risk of hypoglycemia compared to NPH insulin in people with type 1 diabetes
Kolendorf, K
Pavlic-Renar, I
San-Teusanio, F
Philotheou, A
Gall, MA
Heller, S
DIABETES, 2004, 53 : A130 - A131
[24] Quality of life (QoL) assessment of insulin detemir and NPH human insulin in Japanese subjects with diabetes on basal-bolus regimen
Ishii, Hitoshi
Iwamoto, Yasuhiko
Kaku, Kohei
Kawamori, Ryuzo
Tajima, Naoko
Kobayashi, Masashi
DIABETES, 2007, 56 : A710 - A710
[25] iGlarLixi reduces HbA1c to a greater extent than basal insulin therapy regardless of HbA1c levels at screening
Niemoeller, E.
Souhami, E.
Wu, Y.
Jensen, K. H.
DIABETOLOGIA, 2017, 60 : S370 - S371
[26] A basal-bolus regimen of insulin glargine and insulin glulisine results in a lower rate of hypoglycaemia relative to endpoint HbA1c versus twice-daily premixed insulin in type 2 diabetes patients
Fritsche, A.
Larbig, M.
Haering, H. -U.
DIABETOLOGIA, 2010, 53
[27] Less weight gain and hypoglycaemia with once-daily insulin detemir than with NPH insulin in basal-bolus therapy of overweight type 2 diabetes patients: The PREDICTIVE-BMT trial
Montanana, C. Fajardo
Herrero, C. Hernandez
Fernandez, M. Rivas
DIABETOLOGIA, 2007, 50 : S404 - S404
[28] Insulin aspart compared to regular insulin and insulin lispro in basal bolus therapy with NPH to treat pediatric patients with type 1 diabetes mellitus
Arslanian, S
Foster, C
Wright, NM
Stender, S
Hales, P
Hale, D
DIABETOLOGIA, 2005, 48 : A327 - A327
[29] Switching from a human insulin basal-bolus regimen to insulin analog basal-bolus therapy with insulin detemir/insulin aspart improves glycemic control and reduces hypoglycemic episodes in patients with type 1 diabetes:: Results from German subgroup of the PREDICTIVE™ study
Maxeiner, Stephan
Hansen, Jes B.
Nauck, Michael
DIABETES, 2006, 55 : A127 - A127
[30] Cost-effectiveness of detemir versus NPH for type 1 diabetes patients treated with basal-bolus therapy in Portugal
Silva, C.
Alves, C.
Negreiro, F.
Fonseca, M. A.
Aagren, M.
VALUE IN HEALTH, 2008, 11 (03) : A227 - A227

← 1 2 3 4 5 →